Surgical aortic valve replacement produces about twice the carbon footprint of transcatheter approaches: clinical and stewardship implications
Posted inCardiology news Public Health

Surgical aortic valve replacement produces about twice the carbon footprint of transcatheter approaches: clinical and stewardship implications

A life cycle assessment found SAVR emits ~620–750 kg CO2e per case—roughly double OR- or cath-lab TAVR (~280–360 kg CO2e). ICU length of stay and postoperative care were the dominant contributors, highlighting targets for low-carbon perioperative pathways and policy-level decision-making.
SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset
Posted innews Oncology Respiratory

SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset

Two contemporary series show that SMARCA4‑altered NSCLC is molecularly and clinically heterogeneous: squamous tumors have high pathologic responses to neoadjuvant immunochemotherapy, while non‑squamous tumors—especially those with co‑occurring KRAS and STK11/KEAP1 alterations—are immune‑cold and have poor outcomes despite chemoimmunotherapy.
Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis
Posted inCardiology news

Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis

In a multinational registry of patients with concomitant aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR‑CA), both ATTR‑specific therapy (predominantly tafamidis) and aortic valve replacement (AVR) were independently associated with lower mortality. Combined therapy produced outcomes comparable to lone AS treated with AVR.
DOACs trong Bệnh Nhân Rối Loạn Nhịp Tim Atrial Rất Cao Tuổi và Nguy Cơ Xuất Huyết Cao: Một Đội Ngũ Toàn Quốc Hàn Quốc Cho Thấy Lợi Ích Lâm Sàng Tổng Thể
Posted innews

DOACs trong Bệnh Nhân Rối Loạn Nhịp Tim Atrial Rất Cao Tuổi và Nguy Cơ Xuất Huyết Cao: Một Đội Ngũ Toàn Quốc Hàn Quốc Cho Thấy Lợi Ích Lâm Sàng Tổng Thể

Trong một đội ngũ toàn quốc Hàn Quốc gồm bệnh nhân rối loạn nhịp tim atrial (AF) từ 80 tuổi trở lên có nguy cơ xuất huyết cao, các chất chống đông máu đường uống trực tiếp (DOACs) đã giảm thiểu đột quỵ thiếu máu não và tử vong do mọi nguyên nhân so với không sử dụng thuốc chống đông máu, mặc dù có nguy cơ xuất huyết lớn hơn; tổng thể kết quả lâm sàng tổng thể ủng hộ việc sử dụng DOACs.
Widespread Anticoagulation Has Lowered Stroke but Not Intracranial Bleeding in the Very Elderly: Insights from a Danish Nationwide AF Cohort (1999–2022)
Posted inCardiology news

Widespread Anticoagulation Has Lowered Stroke but Not Intracranial Bleeding in the Very Elderly: Insights from a Danish Nationwide AF Cohort (1999–2022)

Danish registry data (1999–2022) show large reductions in stroke across age groups with widespread oral anticoagulant (OAC) uptake, but only modest stroke gains and rising intracerebral hemorrhage in patients ≥85 years, highlighting the need for individualized strategies in the very elderly.
High Early Risk of Sudden Cardiac Arrest in Newly Diagnosed Cardiomyopathy: Insights from the German SCD‑PROTECT Wearable Defibrillator Registry
Posted inCardiology news

High Early Risk of Sudden Cardiac Arrest in Newly Diagnosed Cardiomyopathy: Insights from the German SCD‑PROTECT Wearable Defibrillator Registry

The nationwide SCD‑PROTECT study (n=19,598) found substantial early risk of sustained VT/VF in newly diagnosed ischaemic and non‑ischaemic cardiomyopathy; wearable cardioverter‑defibrillators (WCDs) delivered life‑saving therapy with low inappropriate shock rates while ~52% recovered LVEF >35% during a mean 66‑day WCD period.
Gender‑Affirming Hormone Therapy and Acute Cardiovascular Events: Dutch Cohort Finds Lower MI but Higher VTE in Transgender Women, Elevated MI and Stroke Risk in Transgender Men
Posted inCardiology Diabetes & Endocrinology news

Gender‑Affirming Hormone Therapy and Acute Cardiovascular Events: Dutch Cohort Finds Lower MI but Higher VTE in Transgender Women, Elevated MI and Stroke Risk in Transgender Men

A large Dutch cohort study found that after adjusting for socioeconomic status and lifestyle, transgender women on oestradiol had lower myocardial infarction (MI) risk but higher venous thromboembolism (VTE) risk; transgender men on testosterone had higher MI and ischaemic stroke risk.
Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction
Posted inCardiology Clinical Updates Diabetes & Endocrinology Nephrology news

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction

This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF patients.